Skip to main content

Table 1 Baseline characteristics of the patients (n = 216)

From: The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization

Age (yr), median (range), IQR70 (38–84), 63–76
Gender (Male/Female), n (%)180 (83)/36 (17)
Alcohol/HCV/other etiologies, n (%)97 (45)/ 78 (36)/ 41 (19)
Prior radiological ascites (no / yes), n (%)198 (92) / 18 (8)
Diuretic treatment (no/yes, not available), n (%)133 (62)/67 (31)/16 (7)
Esophageal varices (yes/no/not available), n (%)72 (33)/131 (61)/13 (6)
Child-Pugh (A5/A6/B/ not available), n (%)139 (64)/39 (19)/18 (7.4)/20 (9.6)
BCLC-B (0/A/B), n (%)10 (5)/77 (37)/129 (58)
Bilirubin (mg/dL), median (range), IQR1 (0.2–5.4), 0.93–1.33
Albumin, (g/L), median (range), IQR40 (27–49), 36–43
AFP (ng/mL), median (range), IQR12.8 (0.3–13-000), 4.9–60.3
Cr (mg/dL), median (range), IQR0.84 (0.43–3.96), 0.72–0.99
Sodium (mEq/L), median (range), IQR141 (130–146), 138–142
AST (IU/L), median (range), IQR50 (15–285), 32–84
ALT (IU/L), median (range), IQR38 (7–278), 25–76.5
GGT (IU/L), median (range), IQR120 (16–2011), 67–212
AP (IU/L), median (range), IQR108 (36–370), 86.5–138.5
PT (%), median (range), IQR84 (36–118), 75–94
Platelets (× 109/L), median (range), IQR113 (22–460), 79–159
Hemoglobin (g/dL), median (range), IQR13.6 (7.6–17.9), 12.4–14.9
Clinically Significant Portal Hypertension (yes/no), n157 (73) / 59 (27)
Main nodule diameter (mm), median (range), IQR35 (11–100), 23–48
Previous treatment (ablation/resection), n (%)44 /8
ALBI 1/2/3/not available, n81 /96/1/38
Beads size 300–500 μm/ 100–300 μm, n135/81
Use of Cone Beam CT (no/yes), n187/29
Dose of doxorubicin (mg), median (range), IQR90 (7.5–150), 70–140
  1. Yr Year, IQR Interquartile range, HCV Hepatitis C virus, BCLC Barcelona Clinic Liver Cancer, AFP Alpha-fetoprotein, Cr Serum creatinine, AST Aspartate aminotransferase, ALT Alanine aminotransferase, GGT Gamma-glutamyl-transpeptidase, AP Alkaline phosphatase, PT Prothrombin time